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Abstract 
In this study we analyzed the chondrogenic potential of subpopulations of mesenchymal stem cells (MSCs) derived 
from human synovial membranes enriched for CD73, CD106, and CD271 markers. Subpopulations of human 
synovial membrane MSCs enriched for CD73, CD106, and CD271 markers were isolated using a cytometry sorter 
and characterized by flow cytometry for MSC markers. The expression of Sox9, Nanog, and Runx2 genes by these 
cells was measured by reverse transcriptase-polymerase chain reaction. The chondrogenesis of each subpopulation 
was assessed by culturing the cells in a defined medium to produce spontaneous spheroid formation and 
differentiation towards chondrocyte-like cells. The examination of the spheroids by histological and 
immunohistochemical analyses for collagen type II (COL2), aggrecan, collagen type I (COL1), metalloprotease 13 
(MMP13), and collagen type X (COLX) levels were performed to assess their chondrogenesis capacity. The 
adipogenesis and osteogenesis potential of each subpopulation was determined using commercial media; the resulting 
cells were stained with oil red O or red alizarin to test the degree of differentiation. The subpopulations had different 
profiles of cells positive for the MSC markers CD44, CD69, CD73, CD90, and CD105 and showed different 
expression levels of the genes Sox9, Nanog, and Runx2 involved in chondrogenesis, undifferentiation, and 
osteoblastogenesis, respectively. Immunohistochemical analysis demonstrated that COL1, COL2, COLX, MMP13, 
and aggrecan were expressed in the spheroids as soon as 14 days of culture. The CD271+ subpopulation expressed the 
highest levels of COL2 staining compared to the other subpopulations. CD105 and Runx2 were shown by 
immunohistochemistry and genetic analysis to have significantly higher expression CD271+ subpopulation than the 
other subpopulations. Spheroids formed from CD271-enriched and CD73-enriched MSCs from normal human 
synovial membranes mimic the native cartilage extracellular matrix more closely than CD106+ MSCs and are 
possible candidates for use in cartilage tissue engineering. Both cell types have potential for promoting the 
differentiation of MSCs into chondrocytes, presenting new possibilities for achieving intrinsic cartilage repair. J. Cell. 
Biochem. 111: 834–845, 2010. 
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Articular cartilage is aneural and relatively avascular, receiving nourishment by diffusion from the 
synovial fluid. The capacity for self-repair of articular cartilage is so limited that loss of articular cartilage 
from injury or disease presents major clinical challenges. Because of the very poor regenerative capacity 
of cartilage, various surgical techniques for cartilage repair have been devised [Simon and Jackson, 
2006]. There is much interest in the development of alternative, biologic approaches for cartilage repair 
and regeneration [Steinert et al., 2007]. 
Mesenchymal stem cells (MSCs), which have been located in most tissues and organs of the body, can 
differentiate in vitro into a number of cell types, including chondrocytes [Caplan, 1991]. MSCs have been 
transplanted into lesioned joints in animal models in an attempt to repair the defect, but thus far the results 
have been unsuccessful. MSCs have been difficult to characterize because no specific marker has been 
identified. The principal criteria for their identification are adherence to the plastic of tissue culture flasks 
and their fibroblast-like morphology [Prockop, 1997]. Other characteristics of MSCs are the absence of 
expression of such typical hematopoietic antigens as CD34 and CD45, and the expression of such surface 
markers as CD44, CD73, CD90, CD105, and CD166 [Dominici et al., 2006]. 
A recent research trend has been the use of defined subpopulations from the pool of MSCs derived 
from different tissues to determine which of these have the most potential for differentiation toward a 
defined cell lineage [Isakova et al., 2007; Horn et al., 2008; Molloy et al., 2009]. Our recent studies have 
demonstrated that cells from OA synovia express the MSC markers CD44, CD73, CD90, CD105, CD106, 
and CD271. We have also found that the CD105 subpopulation of MSCs from both normal and OA 
human synovial membranes was capable of differentiation toward chondrocyte-like cells [Arufe et al., 
2009]. The presence of these markers in MSCs from human synovial membranes has led to speculation 
about their role in the chondrogenic potential of the MSC population. From the described MSC markers, 
we selected CD73, CD106, and CD271 for examination because previous studies have already been 
performed on their role in differentiation of various cell types [Jo et al., 2007; Zannettino et al., 2008; 
Alexander et al., 2009], although no previous study has focused on their chondrogenesis potential. CD73 
is expressed on subsets of T and B lymphocytes, follicular dendritic, epithelial and endothelial cells. This 
protein has enzymatic activity and catalyzes the dephosphorylation of adenosine monophosphate (AMP) 
to adenosine, suggesting that CD73 mediates co-stimulatory signals in T cell activation and adhesion of 
lymphocytes to the endothelium [Majore et al., 2009a]. The vascular cell adhesion molecule (VCAM), 
also called CD106, is expressed on activated endothelial cells and some tissue macrophages, bone 
marrow fibroblasts and myoblasts. This protein is involved in the transmigration and invasion 
mechanisms of MSCs [Koga et al., 2008; Steingen et al., 2008; Liu et al., 2008]. CD271 is also known as 
nerve growth factor receptor (NGF) and is a neutrophin believed to bind to its cognate receptor on the 
terminal of sympathetic neurons. It regulates their level of target innervation through two mechanisms. 
First, CD271 stimulates the terminal growth of sympathetic neurons, thereby regulating the level of target 
innervation. Second, CD271, in conjugation with other neutrophins, serves as a discriminator allowing 
elimination of neurons that have failed to sequester adequate target space [Jarocha et al., 2008]. Based on 
these data, our aim was to characterize the CD73+, CD106+, and CD271+ subpopulations of MSCs 
derived from human synovial membranes and to assess their chondrogenic capability. 
Materials and Methods 
Tissue Collection 
Normal synovial membranes were obtained from patients undergoing knee amputation who had no 
history of joint disease. All tissues were collected after fully informed consent and ethical approval from 
the supervisor of the CEIC of Galicia (Ethical Committee of Galicia). Twelve patients contributed 
samples to this study. 
Isolation and Culture of MSCs 
Synovial membranes from intact areas of clinically normal joints were harvested and subjected to 
sequential digestion using 1.2 U/ml dispase and 112 U/ml type I collagenase to isolate MSCs, as 
previously described [Kawaguchi et al., 2005; Arufe et al., 2009]. Briefly, monolayer cultures of MSCs 
from synovial membranes were cultured in Dulbecco's Modified Eagles Medium (DMEM) with 15% 
fetal bovine serum (FBS), 1% penicillin, and 1% streptomycin (all from Sigma–Aldrich, St. Louis, MO). 
When the cells achieved 90% confluency, they were separated into CD73+, CD106+, and CD271+ 
subpopulations using a FACS Aria cytometry sorter (BD Bioscience, Madrid, Spain) and anti-human 
CD73 (BD Bioscience), CD106 (Serotec, BioNova Centífica, S.L., Madrid, Spain), and CD271 (Sigma–
Aldrich) antibodies at 10 µl of antibody per 1 × 106 cells in 200 µl of phosphate-buffered saline (PBS). 
After sorting, some cells were seeded into chamber slices and cultured for 24 h in the DMEM, 15% FBS, 
1% penicillin, and 1% streptomycin medium for use in performing immunofluorescence (IF) analysis for 
the MSC markers, CD44, CD69, CD73, CD90, and CD105, using the same protocol described for 
fluorescence-activated cell sorting (FACS) analysis. 
Fluorescence-Activated Cell Sorting (FACS) Analysis 
Cells were fixed in 4% paraformaldehyde in PBS. Following fixation, the cells were washed twice with 
PBS, permeabilized with PBS containing 0.1% Triton X-100 for 10 min and rinse twice with PBS. The 
primary antibodies used were phycoerythrin (PE)-labeled mouse anti-human CD34 (1:20; 
DakoCytomation, S.A., Barcelone, Spain); fluorescein (FITC)-labeled mouse anti-rat CD45 (1:20, 
Serotec, BioNova Centífica, S.L.); FITC-labeled mouse anti-human CD105 (1:100, Serotec); PE-Cy5 
mouse anti-human CD106 (1:20, Serotec); PE-Cy5-conjugated mouse anti-human CD90 (1:20, BD 
Pharmigen); mouse anti-human Ki67 (1:20, Santa Cruz Biotechnology, Inc., Lorenzo e Hijos, A Coruña, 
Spain); mouse anti-CD271 (1:20, Sigma–Aldrich); mouse anti-human CD117 (1:20, Serotec); PE-
conjugated anti-human CD73 (1:20, BD Bioscience); and PE-conjugated mouse anti-human CD166 
(1:20, BD Bioscience). For detection of primary antibodies not directly labeled, cells were washed with 
PBS, then incubated with 1:1,000 polyclonal rabbit anti-mouse IgD/PE Rabbit F(ab')2 (DakoCytomation) 
for 30 min at room temperature. The stained cells were washed twice with PBS and 10 × 105 cells were 
analyzed on a FACS Aria flow cytometer (BD Bioscience, Mountain View, CA). FACS data were 
generated using DIVA software (BD Bioscience). Negative control staining was performed using FITC-
conjugated mouse IgG1k isotype, PE-conjugated mouse IgG1k isotype, and PE-Cy5-conjugated mouse 
IgG1k isotype (all from BD Bioscience). 
Chondrogenic Differentiation 
CD73+, CD106+, and CD271+ subpopulations were cultured in DMEM, 15% FBS, 1% penicillin, 1% 
streptomycin, and 1.5 × 10−4  M monothioglycerol (MTG) until 90% confluent. Cells were then seeded in 
96-well plates (Sarstedt, Inc., Barcelone, Spain) at 2 × 104 cells per well in a different culture medium 
(DMEM, 15% FBS, 1% penicillin, 1% streptomycin, 1.5 × 10−4  M of MTG, 5 mg/ml ascorbic acid (AA), 
6 µg/ml transferrin (TRANS) (all from Sigma–Aldrich)). The cells were cultured for 2 days to allow 
spontaneous spheroid formation; the medium was again changed to differentiate the cells. The cells were 
cultured for 14, 28, or 46 days in a chondrogenic medium [DMEM, with 15% knockout serum (Gibco, 
Invitrogen, Barcelone, Spain), 5 mg/ml AA, 6 µg/ml TRANS, 10 µM dexamethasone (DEX), 1 × 10−7 M 
retinoic acid, and 1 ng/ml recombinant human transforming growth factor-β3 (rhTGF-β3) (ProSpec-Tany 
TechnoGene, City, IL)]. The medium was changed every 3 days. 
Adipogenic and Osteogenic Differentiation 
CD73+, CD106+, and CD271+ MSC subpopulations from normal synovial membranes were cultured in 
adipogenic and osteogenic commercial media (Cambrex, Lonza, A Coruña, Spain), following the 
manufacturer's instructions, to assess the potential of these subpopulations to differentiate toward these 
mesodermal cell lineages. After 21 days in culture, adipogenic culture plates were fixed in 10 mM sodium 
periodate, 2% paraformaldehyde, 75 mM L-lysine dihydrochloride, and 37.5 mM sodium phosphate 
(dibasic), at pH 7.4 (all from Sigma–Aldrich), for 15 min at room temperature. They were then air-dried 
and stained in a filtered solution of 0.3% oil red O to reveal lipid droplets in the cultures. The osteogenic 
cultures were stained with alizarin red to reveal calcium deposits after 21 days in culture. After fixation, 
the cells were covered with alizarin red S solution (2% aqueous solution [pH 4.2]; Sigma–Aldrich) for 
3 min. The cultures were then washed thoroughly with distilled water. 
RNA Extraction and cDNA Synthesis 
Total RNA was extracted from cultured cells using the Trizol L.S. reagent method (Invitrogen). Reverse 
transcription (RT) was carried out using the Superscript II system (Invitrogen). Total RNA (2 µg) was 
reverse transcribed in a 20 µl reaction volume containing Superscript II (200 U), random primers 
(25 µM), and dNTP (0.5 mM each) at 42°C for 50 min. 
Real-Time Polymerase Chain Reaction (PCR) Analysis 
Genes for human SOX9, Nanog, Runx2, and β-actin were used. Details of the primers and specific 
annealing temperatures used are shown in Table I. The amplification program consisted of an initial 
denaturation step at 92°C for 2 min followed by 40 cycles at 92°C for 15 s, an annealing step at 55–62°C 
depending on the gene used, for 30 s, and an extension step at 72°C for 15 s. Each PCR analysis was done 
in duplicate, with each set of assays repeated three times. To minimize the effects of unequal quantities of 
starting RNA and to eliminate potential sources of inconsistency, the expression level of each gene was 
normalized to that of β-actin using the method [Livak and Schmittgen, 2001]. The controls 
contained no reverse transcriptase.  
Table I. Specific Primers for Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Amplification Are Listed 
With Specific Annealing Temperatures 
Gene name Fw primer Rv primer mRNA ID AT (°C) 
     
SOX9 2f2r gtacccgcacttgcacaac tcgctctcgttcagaagtctc NM_000346 60 
NANOG atgcctcacacggagactgt aagtgggttgtttgcctttg NM_024865 60 
RUNX2 gtgcctaggcgcatttca tgactggcggcgtgcaag NM_001024630 60 
b-ACTIN agagctacgagctgcctgac ggatgccacaggactcca NM_001101 60 
     
 
Fw, forward; Rv, reverse; AT, annealing temperature. 
Histological and Immunohistochemical Analysis of Spheroids 
Following differentiation into chondrocyte-like cells, spheroids containing CD73+, CD106+, or CD271+ 
MSCs were frozen in OCT embedding matrix (BDH Chemicals, Poole, UK). Full-depth 4 µm sections 
were cut using a cryostat and fixed in 4% (w/v) paraformaldehyde (Sigma–Aldrich) in PBS at pH 7.6. 
Some sections were stained with hematoxylin and eosin to evaluate the distribution of matrix or Safranin 
O (all from Sigma–Aldrich) for proteoglycan. Other sections were immunostained using monoclonal 
antibodies directed against COL1 (1:1,000), COL2 (1:50), aggrecan C-20 (1:100), COLX (1:2,000), and 
MMP-13 (1:1,000) (all from Southern Biotechnologies, Birmingham, AL). Biotinylated secondary 
antibodies were detected using peroxidase-labeled biotin–streptavidin complex (Vectastain Elite kit; 
Vector Laboratories, Peterborough, UK) with diaminobenzidine substrate (Vector Laboratories) 
(1:1,000). Native cartilage and skin were used as positive controls for detection of COL2, aggrecan, 
COL1, COLX, and MMP13 (data not shown). Normal mouse serum was used as the negative control; 
these sections were not counterstained. 
Densitometry Analysis 
AnalySIS Image Processing (Soft Imaging System GmbH V. 5.0, Olympus, Münster, Germany) was used 
to quantify the amount of antibodies obtained by immunohistochemical analysis. The data represent the 
analysis of sections of spheroids containing chondrocyte-like cells engineered in vitro from the CD73+, 
CD106+, and CD271+ subpopulations at 14, 28, and 46 days of chondrogenic differentiation compared to 
the negative control. To summarize, three fields of 200 µm2 for each antibody at each time point studied 
were quantified using arbitrary units assigned by the computer program for immunohistochemistry 
values. The plotted values for IF, osteogenic, and adipogenic analyses are the percentage of positive cells 
for each marker studied. For chondrogenesis analysis using AnalySIS Image Processing, the values are 
expressed in arbitrary units reflecting the staining intensity of sections examined using the same 
magnification and light microscopy conditions. The stain intensity was normalized to the intensity signal 
observed in the negative control tissue, which was incubated only with secondary antibody. Using 
AnalySIS Image Processing, the ratios of COL2/aggrecan, COL2/COL1, and aggrecan/COL1 were used 
as indicators of chondrogenesis. Similarly, the ratios of COLX/COL2, MMP13/COL2, and COL1/COL2 
were used as indicators of hypertrophy. 
Statistics 
All experiments were performed in triplicate and one representative data set is shown in the figures. The 
statistical analysis performed between subpopulations and times studied used analysis of variance 
(ANOVA) and the Students' t-test using SPSS 16.0 software. A P-value <0.05 was considered statistically 
significant. SEM was shown in error bars.  
Results 
Characterization of Cells 
Flow cytometry analysis of cells isolated from the synovial membrane before sorting the subpopulations 
showed that the percentage of cells positive for CD44 and CD90 markers was 70–90%, the percentage of 
cells positive for Ki67, CD73, CD166 was 40–50% and the percentage of cells positive for CD106, 
CD105, CD271, CD117 was 20–30% (Fig. 1). In contrast, the cells positive for hematopoietic markers 
were not detectable, the percentage of cells positive for both the CD45 and CD34 markers was <1%. 
These results indicate that cells from synovial tissue obtained through this process are cells expressing 
specific MSC markers. 
 
 
 
Figure 1. Expression of typical mesenchymal stem cell (MSC) markers in the total population of mesenchymal stem cells isolated 
from synovial membranes. Flow cytometry analysis of Ki67, CD34, CD90, CD44, CD73, CD106, CD45, CD105, CD166, CD271, 
and CD117 markers from synovial membrane MSCs before sorting the subpopulations of interest. For each analysis, the antibody 
used for each marker is given at the top of the plot and the fluorochrome measured is given at the bottom the plot. The percentage of 
positive cells is indicated in each plot. FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP-Cy5, phycoerythrin CP-Cy5. 
Characterization of the CD73+, CD106+, and CD271+ synovial membrane MSC subpopulations was 
made by flow cytometry analysis before and after sorting to evaluate the selective enrichment of CD73+, 
CD106+, and CD271+. The purity grades achieved by the separation were between 95% and 99%, 
indicating high purity of the subpopulations for each membrane protein (Fig. 2). IF analysis of the sorted 
subpopulations were performed to detect differences in the expression of characteristic MSC markers 
(Fig. 3). CD44, CD69, CD73, CD90, and CD105 were tested in each subpopulation. We found that the 
CD73+ subpopulation of MSCs had a high percentage of CD44, CD69, and CD90, with more that 50% of 
cells positive for all these markers and a lower percentage, <40%, of cells positive for the CD105 marker. 
The CD106+ subpopulation had more than 60% of cells positive for all the markers tested. Conversely, 
we observed that the CD271+ subset of MSCs derived from synovial membranes had more that 80% of 
cells positive for of CD69, CD90, and CD105 and <40% of positive cells for the CD44 and CD73 
markers. These results may indicate that the subpopulation enriched for CD106 was less differentiated 
because of the high positive percentage of the other markers, while the CD73+ and CD271+ 
subpopulations were appreciably more differentiated. 
To test the differentiation stage of each subpopulation after sorting, real-time reverse transcriptase-
polymerase chain reaction (RT-PCR) was performed for the expression of Sox9, Nanog, and Runx2 genes 
(Fig. 4). All measurements were normalized to the gene expression of the pooled MSCs before sorting. 
The CD73+ subpopulation had a significantly higher expression of Sox9 than the CD106+ and CD271+ 
subpopulations (P < 0.05). The CD106+ subpopulation had significantly higher expression of Nanog than 
did the CD73+ and CD271+ subpopulations (P < 0.05). No differences in the expression of Sox9 and 
Nanog genes were found between CD73+ and CD271+ subpopulations. However, Runx2 gene expression 
in the CD271+ subpopulation was significantly higher than in the other two subpopulations (P < 0.05). 
 
 
 
Figure 2. Characterization of CD73+, CD106+, and CD271+ mesenchymal stem cell (MSC) subpopulations isolated from synovial 
membranes. Flow cytometry analysis of these subpopulations showing selective enrichment of MSC cells expressing. A: Selective 
enrichment of CD73+-expressing cells. Fluorescence-activated cell sorting (FACS) analysis of the subpopulation of CD73+ before 
(left) and after (right) sorting from MSCs of synovial membranes. B: Selective enrichment of CD106+-expressing cells. 
Fluorescence-activated cell sorting (FACS) analysis of the subpopulation of CD106+ before (left) and after (right) sorting from 
MSCs of synovial membranes. C: Selective enrichment of CD271+-expressing cells. Fluorescence-activated cell sorting (FACS) 
analysis of the subpopulation of CD106+ before (left) and after (right) sorting from MSCs of synovial membranes. For each analysis, 
the antibody used for each marker is given at the top of the plot and the fluorochrome measured is given at the bottom the plot. The 
percentage of positive cells is indicated in each plot. FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP-Cy5, 
phycoerythrin CP-Cy5. 
 
 
 
 
 
 
 
 
Figure 3. Immunofluorescence (IF) analysis of the synovial membrane-derived subpopulations of mesenchymal stem cells (MSCs) 
for characteristic MSC markers. Characteristic markers of MSCs, including CD44, CD69, CD73, CD90, and CD105, were tested in 
each subpopulation after sorting. A: CD73+ subpopulation; (B) CD106+ subpopulation; (C) CD271+ subpopulation; (D) a plot 
quantifying the expression of the antibodies obtained by immunohistochemical analysis. The AnalySIS Image Processing computer 
program was used. The names of the markers are on the right of each panel. For each subpopulation, the left panel shows 4′,6-
diamidino-2-phenylindole (DAPI) staining of the cell nucleus, the middle panel shows staining by the antibodies linked to 
fluorescein (FITC) or phycoerythrin (PE) fluorocrome as indicated, and the right panel shows the merged images (magnification 
10×). *P < 0.05 by ANOVA was considered significant. 
 
 
 
Figure 4. Genes involved in the pluripotency expressed by CD73+, CD106+, and CD271+ mesenchymal stem cell (MSC) 
subpopulations. The expression of Sox9, Nanog, and Runx2 genes was studied by real-time RT-PCR analysis. Each experiment was 
done in duplicate, with each set of assays repeated three times. Values are arbitrary units (AU) assigned to the cycles from a 
computer program as described in the Materials and Methods Section. *P < 0.05 by ANOVA was considered significant. 
 
 
 
 
 
 
Differentiation Capacity of Cell Subpopulations 
Adipogenesis and osteogenesis analyses were used as biological markers to insure that the CD73+, 
CD106+, and CD271+ MSC subpopulations were adult stem cells capable of differentiation into other 
mesodermal cell lineages (Fig. 5). Significant differences were found in adipogenesis between the CD73+ 
MSC subpopulation (34%) and the CD106+ (63%) and CD 271+ (73%) subpopulations (P < 0.05). On the 
other hand, the CD73+ MSC subpopulation was best at differentiating into osteocytes (56%), while the 
CD106+ subpopulation produced only 12% and the CD271+ subpopulation produced only 20%. 
 
 
 
Figure 5. Differentiation of CD73+, CD106+, CD271+ mesenchymal stem cell (MSC) subpopulations into mesodermal cell lineages. 
A: CD73+ subpopulation; (B) CD106+ subpopulation; (C) CD271+ subpopulation; the left panels show differentiation towards 
adipocytes and the right panel shows differentiation towards osteocytes (magnification 10×). The cells were cultured for 21 days in 
specific differentiation media. Oil red O and Alizarin red were used to stain adipocytes and osteoblasts, respectively. D: Plot 
showing quantification of the expression of different antibodies obtained by immunohistochemical analyses and analyzed by the 
AnalySIS Image processing computer program. *P < 0.05 by ANOVA was considered significant. Statistical significance between 
groups at the same culture times are indicated by an asterisk. 
 
Chondrogenesis and hypertrophy studies are summarized in Table II. These studies focused on the 
detection by immunohistochemical analysis of the expression of chondrogenic markers, like COL2, 
aggrecan, COL1, COLX, and MMP13, by the subpopulations at 14, 28, and 46 days in chondrogenic 
medium during the differentiation process (Fig. 6). The AnalySIS Image computer program was used for 
measurement (Fig. 7). The CD73+ MSC subpopulation showed significantly higher levels (P < 0.05) of 
expression of COL2 and aggrecan at all time-points than did the CD106+ MSC subpopulation. The 
CD271+ subpopulation had a significantly higher intensity of COL2 and aggrecan staining than the other 
two subpopulations (P < 0.05). The CD106+ MSC subpopulation showed the lowest COL2 and aggrecan 
staining intensity values overall. All data were normalized to the stain intensity obtained in the same 
tissue incubated with only the secondary antibody. COL2/aggrecan, COL2/COL1, and aggrecan/COL1 
ratios were calculated using immunohistochemistry analysis of sections of spheroids obtained from 
chondrocyte-like cells engineered from CD73+, CD106+, and CD271+ MSC subpopulations at 14, 28, and 
46 days of chondrogenic differentiation in vitro. The results of this chondrogenesis analysis were 
compared to the negative control using AnalySIS Image Processing (Fig. 7A–C). The chondrogenesis 
results, reflected by the aggrecan/COL1 and COL2/COL1 ratios, were significantly lower for the CD106+ 
subpopulation at every time point (0.87 ± 0.05; 0.83 ± 0.03; 0.74 ± 0.02 for aggrecan/COL1 and 
1.16 ± 0.05; 1.20 ± 0.05; 1.1 ± 0.05 for COL2/COL1 at 14, 28, and 46 days, respectively) than those of the 
CD73+ (1.64 ± 0.05; 1.9 ± 0.03; 1.3 ± 0.02 for aggrecan/COL1 and 1.65 ± 0.05; 1.59 ± 0.05; 1.47 ± 0.05 
for COL2/COL1 at 14, 28, and 46 days, respectively) and CD271+ (1.19 ± 0.05; 1.38 ± 0.03; 1.67 ± 0.02 
for aggrecan/COL1 and 1.28 ± 0.05; 1.69 ± 0.05; 1.65 ± 0.05 for COL2/COL1 at 14, 28, and 46 days, 
respectively) subpopulations (P  < 0.05). The ratios of COLX/COL2, MMP13/COL2, and COL1/COL2 to 
detect hypertrophy were generated by immunohistochemistry analysis of sections of spheroids obtained 
from chondrocyte-like cells engineered from CD73+, CD106+, and CD271+ subpopulations of MSCs at 
14, 28, and 46 days of chondrogenic differentiation and compared to the negative control using AnalySIS 
Image Processing (Fig. 7D–F). The COLX/COL2 values were significantly higher (1.12 ± 0.02) at 46 
days of chondrogenic differentiation culture of the CD106+ subpopulation of MSCs than in the CD73+ 
(0.59 ± 0.04) and CD271+ (0.89 ± 0.03) subpopulations at the same time point (P < 0.05).  
Table II. Summary of Phenotypic, Genotypic, and Chondrogenic Biomarkers in Mesenchymal Stem Cell (MSC) Subpopulations 
Expressing CD73, CD106, and CD271 
 CD73 CD106 CD271 
    
Phenotypic marker    
CD44 70.3 ± >2.6 68.3 ± 4.4 32.6 ± 5* 
CD69 65 ± 2.8 90 ± 3 83.5 ± 3.1 
CD73 — 98 ± 1.5 34 ± 13* 
CD90 99.6 ± 0.3 96.3 ± 3 82.3 ± 4 
CD105 36.6 ± 3.3 75 ± 2.8 85 ± 2.8 
Genotypic marker    
Sox9 0.44 ± 0.08 0.19 ± 0.06* 0.21 ± 0.03 
Nanog 2.23 ± 0.03 7.60 ± 0.04* 2.65 ± 0.01 
Runx2 0.78 ± 0.14 1.08 ± 0.10 1.46 ± 0.03* 
Chondrogenic marker    
COL2 204.5 ± 2.6 169.3 ± 4.4* 220.4 ± 5 
Aggrecan 182.9 ± 2.8 169.3 ± 3 144.2 ± 3.1 
COL1 139 ± 5 102.3 ± 5* 194 ± 13 
MMP13 161 ± 3 49.5 ± 2.8* 188.8 ± 2.8 
COLX 122.6 ± 3 138.4 ± 3* 192.9 ± 4 
Chondrogenesis    
COL2/aggrecan 1.23 ± 0.03 0.98 ± 0.02 1.48 ± 0.03* 
COL2/COL1 1.47 ± 0.02 1.1 ± 0.01* 1.65 ± 0.02 
Aggrecan/COL1 1.3 ± 0.01 0.74 ± 0.02* 1.67 ± 0.03 
Hypertrophy    
COLX/COL2 0.59 ± 0.04 1.12 ± 0.02* 0.89 ± 0.02 
MMP13/COL2 0.78 ± 0.03 0.92 ± 0.03 0.87 ± 0.04 
COL1/COL2 0.68 ± 0.03 0.60 ± 0.02 0.70 ± 0.09 
    
 
Col1, collagen type I; Col2, collagen type II; COLX, collagen type X; MMP13, metalloproteinase 13. 
The phenotypic marker results show the percentage of cells positive for the MSC markers, CD44, CD69, CD73, CD90, and CD105 
determined by the use of analysis image processing. The immunofluorescent (IF) pictures were obtained using an Olympus 
microscope to view cultures from CD73+, CD106+, and CD271+ subpopulations. The genotypic marker results show values for the 
relative expression of the non-differentiation genes Sox9, Nanog, and Runx2 found in the sorted CD73+, CD106+, and CD271+ 
subpopulations. The relative expression level of each gene was normalized to that of β-actin using the method [Livak and 
Schmittgen, 2001]. The control experiments contained no reverse transcriptase. The chondrogenic marker results were also 
developed using AnalySIS Image Processing. The data represent the analysis of sections of spheroids containing chondrocyte-like 
cells engineered from CD73+, CD106+, and CD271+ subpopulations at 46 days of chondrogenic differentiation culture, compared to 
the negative control. The chondrogenesis results show the ratios COL2/aggrecan, COL2/COL1, and Aggrecan/COL1 and the 
hypertrophy results show the ratios of COLX/COL2, MMP13/COL2, and COL1/COL2, also obtained using AnalySIS Image 
Processing. These data also represent the analysis of sections of spheroids containing chondrocyte-like cells engineered from 
CD73+, CD106+, and CD271+ subpopulations at 46 days of chondrogenic differentiation culture, compared to the negative control. 
* 
P < 0.05 by ANOVA was considered significant. 
 
 
 
Figure 6. Collagen type II (COL2) immunohistochemistry analysis of spheroids engineered from CD73+, CD106+, CD271+ 
mesenchymal stem cell (MSC) subpopulations at 14, 28, and 46 days of culture in a chondrogenic medium. A: Representative 
images of spheroids at 14, 28, and 46 days of differentiation in chondrogenic medium and the negative control for each 
subpopulation after 46 days of culture were shown. See the Materials and Methods Section for details. B: Collagen type II (COL2) 
gene expressed by CD73+, CD106+, and CD271+ mesenchymal stem cell (MSC) subpopulations by real-time RT-PCR analysis. 
Each experiment was done in duplicate, with each set of assays repeated three times. Values are arbitrary units (AU) assigned to the 
cycles from a computer program as described in the Materials and Methods Section. *P < 0.05 by ANOVA was considered 
significant. 
 
 
 
Figure 7. Immunohistochemistry analysis of spheroids engineered from CD73+, CD106+, CD271+, mesenchymal stem cell (MSC) 
subpopulations after 14, 28, and 46 days of culture in chondrogenic medium. The plot quantifies the expression of the different 
antibodies obtained by immunohistochemical analysis and the AnalySIS Image processing computer program. *P < 0.05 by 
ANOVA was considered significant and is indicated by * where the difference between groups at the same time of culture is 
significant. 
Discussion 
The ability to characterize MSCs remains challenging. Hematopoietic stem cells and MSCs share 
common morphological and adherence characteristics. In our study, the expression of typical MSC 
markers in the unsorted population of synovial membrane MSCs, as detected by flow cytometry analysis, 
revealed high levels of CD44, CD90, and CD105, whereas the expression of the CD proteins typical for 
hematopoietic cells was undetectable. Similar results have been found by others, indicating that our 
MSCs isolated from synovial membranes correspond to characteristics typical of MSCs from other 
sources, such as the umbilical cord [Majore et al., 2009b], bone marrow [Delorme and Charbord, 2007], 
and placenta [Mariotti et al., 2008]. These findings suggest that the MSC-like cells present in the total 
population of cells isolated from the synovial membrane meet the criteria for MSCs of the International 
Society for Cellular Therapy [Dominici et al., 2006]. We observed a high level of enrichment in each of 
the subpopulations of MSCs after separation from the total pool using the FACS Aria system (Fig. 2). 
Values achieved were 99% in CD73+ MSC subpopulation, 99% in CD106+, and 95% in CD271+. These 
data are indicative of a high degree of purity attained by the separation process [Jin et al., 2009]. 
CD73 is considered to be one of the multiple markers for MSCs [Nesti et al., 2008]. We considered 
this protein to be a good candidate to use for sorting MSCs and for studying their chondrogenic potential. 
This decision was facilitated by the work of other authors using different sources of MSCs, including 
postnatal thymus [Mouiseddine et al., 2008], bone marrow [Peister et al., 2004], and human mesenchymal 
progenitor cells derived from subchondral cortico-spongious bone [Neumann et al., 2008]. Neumann et al. 
2008 tested the chondrogenic capacity of a subpopulation positive for CD73, CD90, CD105, and STRO1. 
The analysis of our CD73+ MSC synovial membrane subpopulation by IF indicated a high percentage of 
cells positive for MSC markers, such as CD44, CD90, and CD69, and few (<40%) cells positive for 
CD105. Because flow cytometry after sorting showed the CD73+ MSC subpopulation to be 95% positive 
for CD73 (Table II), we did not test this subpopulation for CD73 antigen by IF. The expression of Sox9, 
which is a key transcription gene in chondrogenesis, in the CD73 subpopulation was significantly higher 
than in the other two subpopulations, as shown by real-time RT-PCR (Table II), suggesting that this 
subpopulation is good suited for chondrocyte differentiation, having less adipogenic potential and the best 
osteogenic potential of the subpopulations studied. However, the CD73+ MSC subpopulation had a low 
percentage of cells positive for CD105, compared to the other subpopulations. The CD73+ MSCs 
expressed high levels of COL2 and aggrecan during direct chondrogenic differentiation, and their levels 
of COL1, COLX, and MMP13 was stable during the process. Considering all these observations, we 
believe the CD73+ subpopulation possesses good chondrogenic potential. 
CD106 is a vascular cell adhesion molecule-1 (VCAM-1) that showed a clear correlation with the 
differentiation potential; the CD106+ MSC subpopulation was less osteogenic and more adipogenic than 
the CD73+ MSC subpopulation. Further evaluation of the CD106+ MSC subpopulation revealed a high 
percentage of cells positive for CD69, CD73, and CD90 (>90%, Table II) with less expression of cells 
positive for CD44 and CD105 (<70%, Table II). These data are in accordance with the results of Fukiage 
et al. 2008, who demonstrated that the CD106+ fraction contained less osteogenic and more adipogenic 
cells than the CD106− fraction. Their evaluation of the CD106 fraction of bone marrow stroma cell strains 
in early passages clearly predicted the osteogenic and adipogenic potential of this population after the in 
vitro induction of differentiation [Fukiage et al., 2008]; this indicates the usefulness of CD106 as a 
differentiation-predictive marker for bone marrow stromal cells. Liu et al. 2009 also reported that Nanog 
and Oct4 over-expression both improved chondrogenesis. Because Liu et al. used a mouse model and our 
studies used human cells, the differences might be attributable to differences between species studied. We 
assessed chondrogenesis by measuring the expression of relevant cartilage tissue proteins in 
subpopulation cell-containing spheroids using immunohistochemical analyses. Our results indicated that 
the CD106+ MSC subpopulation had the poorest chondrogenic potential, as reflected by COL2 levels 
during the differentiation process (Table II). 
Jarocha et al. 2008 using bone marrow CD271 and CD105 subpopulations, demonstrated that both the 
osteogenic and adipogenic differentiation potential of expanded cells, as assessed by the microscopic 
evaluation of calcium–phosphate deposits and appearance of lipid droplets, did not differ between the 
marker subpopulations. Their gene profile analysis following the osteogenic differentiation process 
confirmed their microscopic observations. The level of the molecular markers for early and late 
osteogenic, adipogenic, and chondrogenic progenitors showed only small differences, which probably did 
not influence the osteogenic differentiation process. The over-expression of Runx2 has been reported to 
positively affect osteoblastic differentiation, including chondrogenic differentiation [Muruganandan et al., 
2009]. Our CD271+ MSC subpopulation had a high (90%) percentage of cells positive for CD69, CD90, 
and CD105 and a decreased percentage (<40%) of cells positive for CD44 and CD73 (Table II). The data 
from studies of different grades of expression of the MSCs markers are reported in the literature [Jo et al., 
2007; Mageed et al., 2007]. Our data indicate that the CD271+ MSC subpopulation has the most 
capability for adipogenic and chondrogenic differentiation; it also had a significantly higher expression of 
Runx2 compared to the other two subpopulations. The CD271+ MSC subpopulation showed the highest 
expression of COL2 at 28 days of chondrogenesis, although we showed the values at 46 days of 
chondrogenic differentiation in Table II for easier comprehension. Kim and Im 2010 compared two 
subpopulations from human bone marrow, CD105+, and CD271+, indicating that the CD271+ 
subpopulation was slightly more chondrogenic than the CD105+ subpopulation. The chondrogenic 
differentiation process used to induce differentiation in the subpopulations examined in this study were 
previously tested to differentiate CD105+ MSCs from synovial membranes by our laboratory [Arufe et al., 
2009]; we found that this process did not induce hypertrophy of the cells [Hopper et al., 2009; Jackson et 
al., 2009]. In the study presented here, we confirmed that no hypertrophy was found in the chondrogenic 
differentiation of our subpopulations. We found no increase in the expression of COL1, MMP13, or 
COLX in the subpopulations throughout the culture period in the chondrogenic medium. 
To our knowledge this is the first study describing an IF approach to delineate phenotypic differences 
between MSC subpopulations derived from synovial membranes. Our overall results indicate that the 
CD106 subpopulation was more undifferentiated because it showed the highest positive percentage of the 
markers CD44, CD69, CD73, CD90, and CD105. The CD73+ and CD271+ subpopulations were more 
differentiated, as shown by the lower expression of the CD105 marker in the CD73-enriched 
subpopulation and lower expression of the CD44 and CD73 markers in the CD271-enriched 
subpopulation. The high level of the CD105 marker in the CD271+ subpopulation could reflect increased 
chondrogenic potential of this subpopulation compared to CD73+, in which expression of CD105 was 
lower [Arufe et al., 2009; Hoben et al., 2009]. In addition, the genetic analysis yielding a high expression 
of Runx2 supports the greater chondrogenic potential of the CD271+ subpopulation. This potential could 
be enabled by the inhibition of chondrogenic differentiated stem cell hypertrophy [Pei et al., 2009]. The 
CD271+ subpopulation had significantly more intense COL2 staining throughout the chondrogenic 
differentiation process than did the other subpopulations (Fig. 7B). The levels of staining for COL1, 
MMP13, and COLX of spheroids of all subpopulations were unchanged through the entire culture period, 
indicating that no hyperthrophy was present in our model of chondrogenesis. 
Conclusions 
We confirmed that the human synovial membrane is a good source of progenitor cells with the capacity to 
differentiate towards several mesodermal cell lineages (adipocytes, osteocytes, and chondrocytes). We 
also found that the subpopulations of MSCs derived from synovial membrane demonstrated the potential 
for differentiation into the osteogenic pathway, as evaluated by increased mineralization, and toward the 
adipogenesis, shown by the increase in oil droplets. The CD271+ MSC subpopulation retained the most 
chondrogenic potential, followed by the CD73+ MSC subpopulation, when compared with the CD106+ 
MSC subpopulation. The MSC markers may provide a new predictive tool for selecting MSC populations 
for differentiation into different mesenchymal cell types. 
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